SCHEMBL4770418

SCHEMBL4770418

O=C(O)c1cc(F)cnc1Nc1ccc(F)c(F)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 7/20 0.49
CSNK2A1 P68400 1/20 0.45
MEN1 O00255 5/20 0.44
KMT2A Q03164 5/20 0.44
KDM4E B2RXH2 1/20 0.44
GAA P10253 1/20 0.44
GFER P55789 1/20 0.44
HSD17B10 Q99714 1/20 0.44
RAB9A P51151 4/20 0.43
NPC1 O15118 3/20 0.43
LMNA P02545 2/20 0.43
MAPT P10636 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
PTGS2 P35354 2/20 0.42
GSK3A P49840 1/20 0.41
GSK3B P49841 1/20 0.41
GMNN O75496 1/20 0.40
ALDH1A1 P00352 1/20 0.40
TTR P02766 1/20 0.40
CYP1A2 P05177 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15638933 0.87 DHODH (0.64) DHODHCSNK2A1MEN1KMT2AGAA
SCHEMBL15636037 0.84 DHODH (0.58) DHODHMEN1KMT2AGAAGFER
SCHEMBL15635777 0.83 LMNA (0.58) DHODHCSNK2A1MEN1KMT2ALMNA
SCHEMBL15636368 0.80 DHODH (0.72) DHODHMEN1KMT2AGAARAB9A
SCHEMBL4879890 0.80 PDE4B (0.49) MEN1KMT2ARAB9ANPC1SMN1; SMN2
SCHEMBL4879896 0.80 PDE4B (0.49) MEN1KMT2ARAB9ANPC1SMN1; SMN2
SCHEMBL869587 0.80 DHODH (0.46) DHODHCSNK2A1MEN1KMT2ARAB9A
SCHEMBL870223 0.80 DHODH (0.53) DHODHMEN1KMT2ALMNAPTGS2
SCHEMBL17110947 0.80 SYK (0.51) DHODHMEN1KMT2ARAB9ALMNA
SCHEMBL870322 0.79 DHODH (0.51) DHODHMEN1KMT2AGAARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080227797-A1 Pyridopyrimidine Derivatives as Pde4 Inhibitors for the Treatment of Inflammatory and Immune Diseases ASTRAZENECA AB (SE) 2008-09-18 US disclosed
EP-1922318-A1 PYRIDOPYRIMIDINE DERIVATIVES AS PDE4 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY AND' IMMUNE DISEASES AstraZeneca AB (SE) 2008-05-21 EP disclosed
WO-2007004958-A1 PYRIDOPYRIMIDINE DERIVATIVES AS PDE4 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY AND' IMMUNE DISEASES ASTRAZENECA AB (SE) 2007-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227797-A1 Pyridopyrimidine Derivatives as Pde4 Inhibitors for the Treatment of Inflammatory and Immune Diseases PDE4A, PDE4B, PDE5A DHODH 181/4885CSNK2A1 2018/4885MEN1 3231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.